 | • レポートコード：MRC2303H206 • 出版社/出版日：360iResearch / 2022年10月11日 • レポート形態：英語、PDF、234ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査資料によると、2021年に670.8億ドルであった世界の慢性閉塞性肺疾患（COPD）治療市場規模は2022年に720.6億ドルとなり、2027年までに年平均7.59％成長して1,040.8億ドルまで拡大すると見込まれています。当書は、慢性閉塞性肺疾患（COPD）治療の世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、薬剤種類別分析（抗生物質、抗コリン薬、β2作動薬、メチルキサンチン、経口コルチコステロイド）、製品別分析（吸入器、ネブライザー）、検査別分析（動脈血ガス検査、CTスキャン、胸部X線検査、遺伝子検査、肺機能検査）、用途別分析（慢性気管支炎、肺気腫、難治性喘息）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、当書内の企業情報としては、Abbott Laboratories、Aché Laboratórios Farmacêuticos S.A、Adamis Pharmaceuticals Corporation、Almirall, S.A.、Aquinox Pharmaceuticals、Astellas Pharma Inc.、AstraZeneca PLC、Bayer AG、Biomarck Pharmaceuticals, Ltd.などが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の慢性閉塞性肺疾患（COPD）治療市場規模：薬剤種類別 - 抗生物質の市場規模 - 抗コリン薬の市場規模 - β2作動薬の市場規模 - メチルキサンチンの市場規模 - 経口コルチコステロイドの市場規模 ・世界の慢性閉塞性肺疾患（COPD）治療市場規模：製品別 - 吸入器の市場規模 - ネブライザーの市場規模 ・世界の慢性閉塞性肺疾患（COPD）治療市場規模：検査別 - 動脈血ガス検査の市場規模 - CTスキャンの市場規模 - 胸部X線検査の市場規模 - 遺伝子検査の市場規模 - 肺機能検査の市場規模 ・世界の慢性閉塞性肺疾患（COPD）治療市場規模：用途別 - 慢性気管支炎における市場規模 - 肺気腫における市場規模 - 難治性喘息における市場規模 ・世界の慢性閉塞性肺疾患（COPD）治療市場規模：地域別 - 南北アメリカの慢性閉塞性肺疾患（COPD）治療市場規模 アメリカの慢性閉塞性肺疾患（COPD）治療市場規模 カナダの慢性閉塞性肺疾患（COPD）治療市場規模 ブラジルの慢性閉塞性肺疾患（COPD）治療市場規模 ... - アジア太平洋の慢性閉塞性肺疾患（COPD）治療市場規模 日本の慢性閉塞性肺疾患（COPD）治療市場規模 中国の慢性閉塞性肺疾患（COPD）治療市場規模 インドの慢性閉塞性肺疾患（COPD）治療市場規模 韓国の慢性閉塞性肺疾患（COPD）治療市場規模 台湾の慢性閉塞性肺疾患（COPD）治療市場規模 ... - ヨーロッパ/中東/アフリカの慢性閉塞性肺疾患（COPD）治療市場規模 イギリスの慢性閉塞性肺疾患（COPD）治療市場規模 ドイツの慢性閉塞性肺疾患（COPD）治療市場規模 フランスの慢性閉塞性肺疾患（COPD）治療市場規模 ロシアの慢性閉塞性肺疾患（COPD）治療市場規模 ... - その他地域の慢性閉塞性肺疾患（COPD）治療市場規模 ・競争状況 ・企業情報 |
The Global Chronic Obstructive Pulmonary Disease Treatment Market size was estimated at USD 67.08 billion in 2021 and expected to reach USD 72.06 billion in 2022, and is projected to grow at a CAGR 7.59% to reach USD 104.08 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Chronic Obstructive Pulmonary Disease Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Drug Type, the market was studied across Antibiotic, Anticholinergic, Beta2-agonists, Methylxanthines, Oral Corticosteroid, and Phosphodiesterase-4 Inhibitors.
Based on Product, the market was studied across Inhalers and Nebulizers.
Based on Test, the market was studied across Arterial Blood Gas Test, CT scan, Chest x-ray Test, Genetic Test, and Lung Functional Test.
Based on Application, the market was studied across Chronic Bronchitis, Emphysema, and Refractory Asthma.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Chronic Obstructive Pulmonary Disease Treatment market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Chronic Obstructive Pulmonary Disease Treatment Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Chronic Obstructive Pulmonary Disease Treatment Market, including Abbott Laboratories, Aché Laboratórios Farmacêuticos S.A, Adamis Pharmaceuticals Corporation, Almirall, S.A., Aquinox Pharmaceuticals, Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biomarck Pharmaceuticals, Ltd., Boehringer Ingelheim International GmbH, Chiesi Farmaceutici S.p.A., F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Grifols, S.A., Johnson & Johnson Services, Inc, Merck & Co., Inc., Mylan N.V., Novartis International AG, Orion Corporation, Sunovion Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., and Theravance Biopharma.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Chronic Obstructive Pulmonary Disease Treatment Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Chronic Obstructive Pulmonary Disease Treatment Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Chronic Obstructive Pulmonary Disease Treatment Market?
4. What is the competitive strategic window for opportunities in the Global Chronic Obstructive Pulmonary Disease Treatment Market?
5. What are the technology trends and regulatory frameworks in the Global Chronic Obstructive Pulmonary Disease Treatment Market?
6. What is the market share of the leading vendors in the Global Chronic Obstructive Pulmonary Disease Treatment Market?
7. What modes and strategic moves are considered suitable for entering the Global Chronic Obstructive Pulmonary Disease Treatment Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing environmental pollution
5.1.1.2. Rapidly growing tobacco and cigarette consumption causing prevalence’s of pulmonary disease
5.1.1.3. Rising global expenditure on medicine and personal care and technological advancements
5.1.2. Restraints
5.1.2.1. Presence of generic drugs in the market
5.1.2.2. Lack of proper awareness about the effect of chronic obstructive pulmonary diseases
5.1.3. Opportunities
5.1.3.1. Research and development activities
5.1.4. Challenges
5.1.4.1. Increased pricing pressures and patent expiries
5.2. Cumulative Impact of COVID-19
6. Chronic Obstructive Pulmonary Disease Treatment Market, by Drug Type
6.1. Introduction
6.2. Antibiotic
6.3. Anticholinergic
6.4. Beta2-agonists
6.5. Methylxanthines
6.6. Oral Corticosteroid
6.7. Phosphodiesterase-4 Inhibitors
7. Chronic Obstructive Pulmonary Disease Treatment Market, by Product
7.1. Introduction
7.2. Inhalers
7.3. Nebulizers
8. Chronic Obstructive Pulmonary Disease Treatment Market, by Test
8.1. Introduction
8.2. Arterial Blood Gas Test
8.3. CT scan
8.4. Chest x-ray Test
8.5. Genetic Test
8.6. Lung Functional Test
9. Chronic Obstructive Pulmonary Disease Treatment Market, by Application
9.1. Introduction
9.2. Chronic Bronchitis
9.3. Emphysema
9.4. Refractory Asthma
10. Americas Chronic Obstructive Pulmonary Disease Treatment Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Chronic Obstructive Pulmonary Disease Treatment Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Chronic Obstructive Pulmonary Disease Treatment Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Abbott Laboratories
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Aché Laboratórios Farmacêuticos S.A
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Adamis Pharmaceuticals Corporation
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Almirall, S.A.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Aquinox Pharmaceuticals
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. Astellas Pharma Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. AstraZeneca PLC
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Bayer AG
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Biomarck Pharmaceuticals, Ltd.
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Boehringer Ingelheim International GmbH
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Chiesi Farmaceutici S.p.A.
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. F. Hoffmann-La Roche Ltd
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. GlaxoSmithKline PLC
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. Grifols, S.A.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Johnson & Johnson Services, Inc
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Merck & Co., Inc.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Mylan N.V.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Novartis International AG
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Orion Corporation
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Sunovion Pharmaceuticals Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Teva Pharmaceutical Industries Ltd.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. Theravance Biopharma
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing